Clinical Trial

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Name: A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC) — clinical trial record (NCT06282159)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: MAGIC

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).

Trial Details

NCT Number	NCT06282159
Lead Sponsor	Dianthus Therapeutics
Conditions	Myasthenia Gravis, Generalized
Enrollment	65 participants
Start Date	2024-02-23
Primary Completion	2025-07-28 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-08